Abstract
Introduction
Cisplatin(CisPt)-based combination regimens form the mainstay of current treatment of various solid malignancies [1] . Unfortunately, CisPt is characterized by some inherited setbacks, which significantly limit its usefulness. Indeed, CisPt has an unfavourable toxicological profile and some common cancers (e.g. colon adenocarcinoma) are intrinsically refractory, whereas in tumours initially sensitive, acquired resistance is often developed in the course of therapy [2] . To avoid these problems, thousands of platinum and other metal-based compounds have been tested for their potential antitumour properties in the last 40 years. A series of compounds showing encouraging perspectives were the phosphine complexes of group 11 metal ions [3] . Their biological properties were little explored until late 1970s when a thioglucose derivative of triethylphosphine gold(I) (auranofin) was found to have antitumour activity in murine models [4] . [5] . Unfortunately, the presence of several phenyl groups appended to the phosphorus donors caused undesired side effects [6] , thus precluding clinical trials. A rational extension of diphosphine gold(I) chemistry to the first row congener copper indicated that analogous copper(I) complexes of 'CuP4' stoichiometry could be efficiently designed [7, 8] . Among them, a series of hydrophilic copper(I) derivatives including the water soluble tris(hydroxymethyl)phosphine (thp) ligand, either alone [9] or in combination with hydrophilic scorpionates were studied [10] . Copper(I,II) complexes investigated for antitumour activity have been recently reviewed [11] [12] [13] .
In an attempt to identify gold complexes with a wider spectrum of activity, BernersPrice demonstrated the antitumour activity of [Au(dppe)2][Cl] (dppe ϭ 1,2-bis(diphenylphosphino)ethane) against a range of tumour models in mice

CP (Fig. 1), a monocationic copper(I) complex highly soluble and stable in water solution, distinguished itself for its remarkable cancer cell killing ability. Against human cancer cells, CP cytotoxic potency was over 40-fold that of CisPt and it was not cross-resist-
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ant with this platinum-based drug; moreover, it was able to overcome the multi-drug resistance phenomenon [9] . It has been proposed that the cytotoxicity of CP may be correlated to its ability to induce a programmed non-apoptotic death termed paraptosis or type-III cell death [9, 14] . Paraptosis lacks of apoptotic morphology such as pyknosis, plasma membrane blebbing, caspase-3 activation and DNA fragmentation [15] , and it is characterized by a massive cytoplasmic vacuolization [15, 16] [17, 18] . Many studies pointed out that copper complexes inhibit proteasome activity in cancer cells [19, 20] [23, 24] .
In 
Materials and methods
Chemicals
CP was prepared as described elsewhere [9] . CisPt, OxPt, MTT (3-(4,5-dimethylthiazol-2-yl 
Cytotoxicity assays MTT
The growth inhibitory effect towards tumour cells was evaluated by means of MTT assay as previously described [9] . Mean absorbance for each drug 
Clonogenic assay
LoVo and CCD-18Co cells ( 
Cytochrome c release
LoVo cells (30 ϫ 10 6 ) were treated for 12 hrs with tested compounds at IC50 concentration. Afterwards, cells were processed and cytochrome c was assessed as previously described [28] .
Mitochondrial membrane potential depletion
Mitochondrial membrane potential (MMP) depletion was determined by measuring the fluorescence of cells stained with tetramethylrhodamine methyl ester (TMRM) as previously described [9] . 
Microscopy analysis Phase contrast microscopy
Transmission electron microscopy analyses
The 10 6 LoVo cells were treated for 24 hrs with IC50 of CP and subjected to transmission electron microscopy (TEM) analyses as previously described [29] . 
Immunofluorescence
Western blot analyses
The 10 
An equal amount of proteins for each sample was electrophoresed on a 12% SDS-PAGE and blotted to a nitrocellulose membrane. The membrane was incubated for 1 hr in PBS-Tween20 (0.05%) containing 5% nonfat milk and then at 37ЊC for 1 hr with primary antibodies (mouse monoclonal anti-ubiquitin and anti-␤-actin, rabbit polyclonal anti-pPERK and anti-pIRE1). The membranes were stained with the corresponding peroxidase-conjugated secondary antibodies for 1 hr at room temperature and detected by ECL according to the manufacturer's protocol (GE).
Proteasome activity
Purified cell extracts. 
Results
Cytotoxicity assays
The 
cancer and CCD-18Co non-tumour colon cells (Fig. 2). Analysis of the stained colonies revealed that CP efficiently abrogated the clonogenic ability of LoVo cells in a dose-dependent manner. Conversely, treatment of CCD-18Co cells with CP did not significantly affect their capacity to form viable colonies and the decrease of survival fraction of CCD-18Co cells was considerably lower than that obtained in LoVo tumour cells.
Cell death induced by CP in colon cancer cells is independent from DNA-fragmentation, caspase activation, cytochrome c release and MMP depletion
We had previously demonstrated that CP induced a caspase-3-independent paraptotic cell death in ovarian cancer cells [9] . The assessment in LoVo cells of the genomic DNA fragmentation (Fig. 3A) and of the apoptosome complex formation (Fig. 3B) Figure 3C , OxPt provoked a substantial activation of all caspases. Figure 3 , showing a reduced DNA fragmentation (Fig. 3B, b) and caspase induction (Fig. 3C, c) Figure 3D shows results obtained after 12 hrs treatment. On the contrary, as previously well documented by literature [34] , OxPt determined a substantial cytohrome c release after 12 hrs exposure (Fig. 3D) . MMP depletion generally precedes apoptotic cell death [31] . However, recent studies underlined a key role of mitochondrial permeability transition pore opening in necrosis and mitotic catastrophe [35, 36] (Fig. 3E) . (Fig. 4A, aЈ) (Fig. 4B) . No signs of classic apoptotic changes, such as cell shrinkage, chromatin condensation and apoptotic body formation were evidenced for both exposure times (Fig. 4B, bЈ, bЈ, bЈЈ) [9, 16, 37] . ER cisternae at first began to increase in abundance and dilated, subsequently an increase of cisternae inner volume and a radical change in ER (Fig. 4C) . Overall, these results clearly confirmed CP-induced vacuoles originated from the ER cisternae as a consequence of ER swelling.
, confirmed the absence of chromatin condensation and DNA fragmentation in the cell death pathway triggered by CP. Indeed, CP cell treatment did not influence neither the electrophoretic migration of the DNA fragments in single-cell gel electrophoresis assay nor mono-and oligo-nucleosome formation. Interestingly, the extent of nucleosomes was even markedly lower than that quantified in control cells. Conversely, OxPt induced a significant increase in comet appearance and a roughly 30-fold increase in histone-DNA formation in 12-hr-treated LoVo cells compared to controls. The activity of the two initiator caspases (-8 and -9), and the downstream effectors (-3/-7 and -6) was analysed to elucidate if caspase(s) mediated CP-induced cell death. As shown in
No increase in free AMC has been detected by using substrates for all caspases in cells exposed to CP for 12 or 24 hrs. Interestingly, a sensible decrease testing caspase-3/-7 and -9 activities could be underlined in CP-treated cells, thus hypothesizing that the copper complex caused a reduction of procaspase-3/-7 and -9 cleavage by upstream proteases or elicited a direct inhibition of these caspases. The results presented in the inserts of
. By treating LoVo cells with IC50 of CP for 12 and 24 hrs, TMRM fluorescence intensity did not decrease but, in contrast, continuously augmented by increasing exposure times
CP induces massive cytoplasmatic vacuoles originated from ER
LoVo colon cancer cells treated for 24 hrs with IC50 of CP and analysed by phase contrast microscopy, revealed evident morphological changes, primarily associated with intracellular vacuolization
CP induces the impairment of the UPS
ER swelling has been increasingly documented as a morphological alteration symptomatic of an ER-proteasome cooperative activity disturbance [18, 19] [38] . (Fig. 5B) (6, 12 and 24 hrs) with IC50 CP (Fig. 5C ). Poly-ubiquitinated aggregosomes were confirmed in 24 hrs CP-treated LoVo cells by means of an immunofluorescence staining (Fig. 5D ). 
. Very recently, Dou et al. reported that certain copper complexes based on mixtures of dithiocarbamate and Cu(II) salts act as proteasome inhibitors in cancer cells
To examine whether CP is capable of inhibiting the proteasome activity, we first tested the functioning of each individual active site of the 26S proteasome under cell-free conditions. CP, tested at increasing concentrations on a purified 26S proteasome extract from LoVo cells, inhibited all the proteolitic activities with IC50 values (M) of 23, 34 and 21 concerning chymotrypsin-like (CT-L), trypsin-like (T-L) and caspase-like (C-L) activity, respectively (Fig. 5A). To further evaluate CP anti-proteasome activity, LoVo cells were treated with increasing concentrations of CP for 24 hrs and then submitted to proteasome activity measurement and estimation of poly-ubiquitinated proteins. The proteasomal CT-L, T-L and C-L activities were decreased by 50% with 31, 42 and 37 M of CP, respectively, thus confirming that CP is able to inhibit all three proteasome activities also in intact cells
Induction of ER stress response by CP
